Similar articles

• Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab.

  Folkmane I, Bicans J, Amerika D, Chapenko S, Murovska M, Rosentals R. Folkmane I, et al. Transplant Proc. 2001 Nov-Dec;33(7-8):3209-10. doi: 10.1016/s0041-1345(01)02366-1. Transplant Proc. 2001. PMID: 11750377 Clinical Trial. No abstract available.
• Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.

  Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J. Ivanovski N, et al. Transplant Proc. 2001 Nov-Dec;33(7-8):3203-4. doi: 10.1016/s0041-1345(01)02363-6. Transplant Proc. 2001. PMID: 11750374 No abstract available.
• Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.

  Kovac D, Kotnik V, Kandus A. Kovac D, et al. Transplant Proc. 2005 Dec;37(10):4230-4. doi: 10.1016/j.transproceed.2005.11.054. Transplant Proc. 2005. PMID: 16387086 Clinical Trial.
• The role of newer monoclonal antibodies in renal transplantation.

  Vincenti F. Vincenti F. Transplant Proc. 2001 Feb-Mar;33(1-2):1000-1. doi: 10.1016/s0041-1345(00)02303-4. Transplant Proc. 2001. PMID: 11267163 Review. No abstract available.
• Acute rejection after heart transplantation.

  Delgado JF, Sánchez V, de la Calzada CS. Delgado JF, et al. Expert Opin Pharmacother. 2006 Jun;7(9):1139-49. doi: 10.1517/14656566.7.9.1139. Expert Opin Pharmacother. 2006. PMID: 16732701 Review.